Introduction While the introduction of biologics has improved the quality of life of patients
with psoriasis and psoriatic arthritis, it may have increased the economic burden of these …

The introduction of biologic disease modifying anti-rheumatic drugs (bMDARDs) have
revolutionised the treatment of psoriatic arthritis (PsA). This combined with a 'treat-to …

Purpose To assess efficacy, safety, and cost-effectiveness of adalimumab (ADA) therapy
optimization in a large series of patients with uveitis due to Behçet disease (BD) who …

Objective Tocilizumab (TCZ) is the only biologic therapy approved for giant cell arteritis
(GCA). There is general agreement on the initial/maintenance dose, duration of TCZ therapy …

Objective The objective was to determine if dose reduction is non-inferior to full-dose TNFi to
maintain low disease activity (LDA) in patients already in remission with TNFi, in axial …

Objective To establish recommendations for the management of patients with rheumatoid
arthritis (RA) to serve as a reference for all health professionals involved in the care of these …

Background: Biological agents used for the treatment of psoriatic arthritis (PsA) and
rheumatoid arthritis (RA) are associated with serious adverse effects (SAEs). Although …

Background The objectives of this study were to assess the discontinuation of biologic
therapy in patients who achieve remission and identify predictors of discontinuation of …

Background Recent data suggest that anti-TNF doses can be reduced in ankylosing
spondylitis (AS) patients. Some authors even propose withdrawing treatment in patients in …

Objetivo Establecer recomendaciones para el manejo de pacientes con artritis reumatoide
(AR) centrado en el papel de los fármacos antirreumáticos modificadores de enfermedad …